Rein Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On July 29, 2026, Rein Therapeutics amended its Certificate of Incorporation to increase authorized share capacity from an unstated prior amount to 205M total shares (200M common at $0.001 par, 5M preferred at $0.001 par). The filing does not disclose shares currently outstanding, reserved, or the reason for this amendment. This is a standard corporate housekeeping action, though the magnitude relative to the company's $32.3M market cap suggests potential dilution capacity.
Why this rating
Routine charter amendment; no issuance occurred yet. Dilution risk exists but is speculative and depends on future capital events.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.